A multimodal approach to accelerate drug discovery and development in Alzheimer’s disease

Project description

Combining genetics and imaging for AD drug discovery

Clinical trials on new drugs against Alzheimer's disease (AD) have failed to show any efficacy in slowing disease progression, underscoring the importance of new therapeutic targets. Towards this goal, the EU-funded MAP-AD project will use autosomal and X chromosome genetic variants to identify novel molecular pathways and putative therapeutic targets. Scientists will decipher the impact of specific genetic variants on gene expression through the analysis of post-mortem brain tissue. Combined with multimodal brain imaging analysis, the genomics information will be applied to correctly enrol patients in clinical trials expediting the development of drugs for the prevention and treatment of AD.

Fields of science

Programme(s)

Topic(s)

MSCA-IF-2019 - Individual Fellowships

Funding Scheme

MSCA-IF-GF - Global Fellowships

Coordinator

INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE

Net EU contribution

€ 257 619,84

Address

Boulevard De L'hopital 47
75013 Paris
France

Region

Ile-de-France Ile-de-France Paris

Activity type

Research Organisations

Links

Contact the organisation Website

Participation in EU R&I programmes

H2020 collaboration network

Non-EU contribution

€ 0,00

Partners (1)

Partner

BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

United States